
Ampio Pharmaceuticals AMPE
Annual report 2023
added 03-27-2024
Ampio Pharmaceuticals Accounts Payables 2011-2026 | AMPE
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 750 K | 97 K | 427 K | 186 K | 151 K | - | - | - | 2.88 M | 3.3 M | 1.9 M | 1.2 M | 631 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.3 M | 97 K | 1.15 M |
Quarterly Accounts Payables Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 459 K | 627 K | 575 K | 97 K | 218 K | 718 K | 1.58 M | 427 K | 307 K | 170 K | 126 K | 186 K | 186 K | 186 K | 186 K | 151 K | 151 K | 151 K | 151 K | 706 K | 707 K | - | - | - | - | - | - | - | 1.15 M | 1.37 M | 2.21 M | 1.8 M | 2.31 M | 1.8 M | 1.8 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 631 K | 631 K | 631 K | 631 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.3 M | 97 K | 1.11 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
2.72 M | $ 3.44 | 2.99 % | $ 303 M | ||
|
Amgen
AMGN
|
2.37 B | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 19.23 | -1.38 % | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Amarin Corporation plc
AMRN
|
45.4 M | $ 14.6 | 0.76 % | $ 6.06 B | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.4 | 2.19 % | $ 357 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
6.75 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
10.6 M | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.23 M | - | -74.18 % | $ 955 K | ||
|
Benitec Biopharma
BNTC
|
201 K | $ 11.19 | 1.91 % | $ 461 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
3.22 M | $ 4.42 | 4.25 % | $ 734 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Cabaletta Bio
CABA
|
4.55 M | $ 2.82 | -4.08 % | $ 3.29 M | ||
|
Calithera Biosciences
CALA
|
3.65 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
11.6 M | - | -3.03 % | $ 260 M | ||
|
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M |